These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 28711377

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio.
    Dasari BV, Roberts KJ, Hodson J, Stevens L, Smith AM, Hubscher SG, Isaac J, Muiesan P, Sutcliffe RP, Marudanayagam R, Mirza DF.
    HPB (Oxford); 2016 Apr; 18(4):332-8. PubMed ID: 27037202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Does blood group affect survival following pancreatoduodenectomy for periampullary malignancy?
    Khalil K, Bansal S, Ayaani S, Hodson J, Lam FT, Khan S, Ahmad J, Isaac J, Muiesan P, Mirza D, Dasari B, Marudanayagam R, Sutcliffe RP, Marangoni G, Roberts KJ.
    HPB (Oxford); 2018 Sep; 20(9):848-853. PubMed ID: 29705345
    [Abstract] [Full Text] [Related]

  • 6. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades.
    He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL.
    HPB (Oxford); 2014 Jan; 16(1):83-90. PubMed ID: 23472829
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.
    Saito T, Nakai Y, Isayama H, Hirano K, Ishigaki K, Hakuta R, Takeda T, Saito K, Umefune G, Akiyama D, Watanabe T, Takagi K, Takahara N, Hamada T, Uchino R, Mizuno S, Mouri D, Yagioka H, Kogure H, Togawa O, Matsubara S, Ito Y, Yamamoto N, Tada M, Koike K.
    Pancreas; 2018 Aug; 47(7):800-806. PubMed ID: 29851751
    [Abstract] [Full Text] [Related]

  • 10. Palliative pancreaticoduodenectomy in pancreatic and periampullary adenocarcinomas.
    Wang SE, Shyr YM, Su CH, Chen TH, Wu CW.
    Pancreas; 2012 Aug; 41(6):882-7. PubMed ID: 22286381
    [Abstract] [Full Text] [Related]

  • 11. Exocrine pancreatic insufficiency following esophagectomy.
    Huddy JR, Macharg FM, Lawn AM, Preston SR.
    Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
    [Abstract] [Full Text] [Related]

  • 12. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.
    Saito T, Hirano K, Isayama H, Nakai Y, Saito K, Umefune G, Akiyama D, Watanabe T, Takagi K, Hamada T, Takahara N, Uchino R, Mizuno S, Kogure H, Matsubara S, Yamamoto N, Tada M, Koike K.
    Pancreas; 2017 Mar; 46(3):341-346. PubMed ID: 28099252
    [Abstract] [Full Text] [Related]

  • 13. Pancreatic enzyme replacement therapy following surgery for pancreatic cancer: An exploration of patient self-management.
    Dunleavy L, Al-Mukhtar A, Halliday V.
    Clin Nutr ESPEN; 2018 Aug; 26():97-103. PubMed ID: 29908691
    [Abstract] [Full Text] [Related]

  • 14. Dramatic improvements in outcome following pancreatoduodenectomy for pancreatic and periampullary cancers.
    Xu H, Bretthauer M, Fang F, Ye W, Yin L, Adami HO.
    Br J Cancer; 2024 Sep; 131(4):747-754. PubMed ID: 38937622
    [Abstract] [Full Text] [Related]

  • 15. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients.
    Barkin JA, Westermann A, Hoos W, Moravek C, Matrisian L, Wang H, Shemanski L, Barkin JS, Rahib L.
    Pancreas; 2019 Jul; 48(6):780-786. PubMed ID: 31210656
    [Abstract] [Full Text] [Related]

  • 16. Factors predicting adequate lymph node yield in patients undergoing pancreatoduodenectomy for malignancy.
    Sierzega M, Bobrzyński Ł, Matyja A, Kulig J.
    World J Surg Oncol; 2016 Sep 20; 14(1):248. PubMed ID: 27644962
    [Abstract] [Full Text] [Related]

  • 17. Risk by indication for pancreaticoduodenectomy in patients 80 years and older: a study from the American College of Surgeons National Surgical Quality Improvement Program.
    Bergquist JR, Shubert CR, Ubl DS, Thiels CA, Kendrick ML, Truty MJ, Habermann EB.
    HPB (Oxford); 2016 Nov 20; 18(11):900-907. PubMed ID: 27594118
    [Abstract] [Full Text] [Related]

  • 18. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
    Petrou A, Soonawalla Z, Silva MA, Manzelli A, Moris D, Tabet PP, Friend P.
    J BUON; 2016 Nov 20; 21(4):874-882. PubMed ID: 27685908
    [Abstract] [Full Text] [Related]

  • 19. Reclassification of tumour origin in resected periampullary adenocarcinomas reveals underestimation of distal bile duct cancer.
    Pomianowska E, Grzyb K, Westgaard A, Clausen OP, Gladhaug IP.
    Eur J Surg Oncol; 2012 Nov 20; 38(11):1043-50. PubMed ID: 22883964
    [Abstract] [Full Text] [Related]

  • 20. Pancreatic exocrine insufficiency after pancreaticoduodenectomy is more prevalent with pancreaticogastrostomy than with pancreaticojejunostomy. A retrospective multicentre observational cohort study.
    Roeyen G, Jansen M, Ruyssinck L, Chapelle T, Vanlander A, Bracke B, Hartman V, Ysebaert D, Berrevoet F.
    HPB (Oxford); 2016 Dec 20; 18(12):1017-1022. PubMed ID: 27726974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.